Bio-Path BPTH offering +8%; LLY meets NSCLC primary endpoint

Price and Volume Movers


Bio-Path Holdings, Inc., (Nasdaq: BPTH) announced a registered direct offering for institutional investors of 712,910 shares of its common stock, at a purchase price of $25.95 per share, for aggregate gross proceeds of approximately $18.5m. Shares closed up 8% to $35.13.


Eli Lilly and Company (NYSE: LLY) announced that its Phase 3 RELAY study of Cyramza (ramucirumab) as a first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC), met its primary endpoint of progression-free survival (PFS).

Zafgen, Inc. (Nasdaq:ZFGN) shares closed down 37% to $2.89 following news late-Monday that it will suspend plans to file an investigational new drug (IND) application for ZGN-1258, its pipeline candidate for Prader-Willi syndrome (PWS), based on findings in muscle tissue in rodent toxicology studies.

Osiris Therapeutics, Inc. (NASDAQ: OSIR) announced it will be acquired by Smith & Nephew plc (LSE:SN, NYSE:SNN) for $19 per share in cash, representing a total equity value of approximately $660m, a marginal premium compared with Monday's close, with shares closing up just 1% to $19.06.


Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume



Aileron Therapeutics, Inc. (ALRN): $2.12; +51%.

Seelos Therapeutics, Inc. (SEEL): $3.85; +20%.

Jounce Therapeutics, Inc. (JNCE): $6.51; +19%.

Dova Pharmaceuticals, Inc. (DOVA): $9.34; +17%.

Aslan Pharmaceuticals Limited (ASLN): $4.38; +17%.


Tonix Pharmaceuticals Holding Corp. (TNXP): $2.97; -12%.

Matinas BioPharma Holdings, Inc. (MTNB): $1.17; -9%.

TrovaGene, Inc. (TROV): $4.44; -8%.

Crinetics Pharmaceuticals, Inc. (CRNX): $23.51; -8%.

Corvus Pharmaceuticals, Inc. (CRVS): $4.07; -8%.



Leave a comment